Product Description
TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3.
Mechanisms of Action: GAL3 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: Orphan Drug - Idiopathic Pulmonary Fibrosis|Pulmonary Fibrosis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galecto Biotech
Company Location: Eastern America
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, France, Georgia, Germany, Ireland, Israel, Italy, Poland, Russia, Spain, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Idiopathic Pulmonary Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03832946 |
GALACTIC-1 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2023-05-17 |
12% |
2024-05-23 |
Patient Enrollment|Primary Endpoints|Treatments |
2018-002664-73 |
2018-002664-73 | P2 |
Completed |
Idiopathic Pulmonary Fibrosis |
2023-05-17 |
12% |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |